Xenon Pharmaceuticals

Company snapshot

Xediton is a privately-held pharmaceutical company with a focus on meeting the needs of patients, physicians and partners. We are committed to developing, partnering and making available new and established medicines to promote the health of Canadians.

• 22 active pipeline program(s) linked via ClinicalTrials.gov.
• 106 US patent(s) indexed to this assignee profile.
• 22 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Xenon Pharmaceuticals. Not investment advice.

• Peer + 0 momentum

  Vanda Pharmaceuticals Netherlands

  TA overlap score 42

• Peer + 0 momentum

  Chongqing Precision Biotech

  TA overlap score 40

• Peer + 0 momentum

  SUPERNUS PHARMACEUTICALS

  TA overlap score 31

• Peer + 0 momentum

  Rapport Therapeutics

  TA overlap score 31

Recent activity

Latest pipeline, patent, and corporate events for Xenon Pharmaceuticals.

1. Jun 8, 2026 Clinical update

   XPF-008-201 — Phase 2

2. Jun 8, 2026 Clinical update

   XEN496 — Phase 3

3. Jun 5, 2026 Clinical update

   XPF-010, Placebo to match XPF-010 — Phase 3

4. Jun 5, 2026 Clinical update

   Placebo, XPF-010 — Phase 3

5. May 26, 2026 Clinical update

   XPF-010 — Phase 3

View all clinical trial activity →

• What is Xenon Pharmaceuticals?

  Xenon Pharmaceuticals is a pharma organization headquartered in Burnaby, CA. It trades on NYSE under ticker XENE. Primary therapeutic focus areas include Major Depressive Disorder, Primary Erythromelalgia, Bipolar Depression, Bipolar Disorder, Focal Epilepsy. NovaPharmaNews links

• Is Xenon Pharmaceuticals publicly traded?

  Yes. Xenon Pharmaceuticals is listed with ticker XENE on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Xenon Pharmaceuticals develop or market?

  We link 2 drug profile(s) where Xenon Pharmaceuticals is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/xenon-pharmaceuticals#company-drugs.

• What are the latest developments for Xenon Pharmaceuticals?

  In the last 12 months our linked public records show 22 trial program update(s) and 1 US patent grant(s) tied to this profile.

• What therapeutic areas does Xenon Pharmaceuticals focus on?

  Xenon Pharmaceuticals focuses on Major Depressive Disorder, Primary Erythromelalgia, Bipolar Depression based on our analysis of their pipeline programs and drug development activities.